1. Affordable SARS-CoV-2 protein vaccines for the pandemic endgame.
- Author
-
Triccas, James A., Kint, Joeri, and Wurm, Florian M.
- Subjects
COVID-19 ,COVID-19 vaccines ,SARS-CoV-2 Delta variant ,BOOSTER vaccines ,SARS-CoV-2 Omicron variant ,VACCINATION - Abstract
The astonishing speed with which coronavirus disease 2019 (COVID-19) vaccines were developed is nothing short of a scientific triumph. The COVID-19 Vaccines Global Access Scheme (COVAX) was established to facilitate global COVID-19 vaccine distribution; however, COVAX is underfunded, has struggled to secure enough vaccine doses and has failed to meet many key targets. When combined with an affordable adjuvant, a sub-dollar per dose COVID-19 vaccine is feasible; this contrasts with the high cost of mRNA vaccines and complexities around their manufacture and access to intellectual property[12]. It is clear that global vaccine production and supply need to be increased, ideally through the building of vaccine manufacturing and distribution capacity in LMICs. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF